ClinicalTrials.gg
CompletedNCT03189537Updated Jun 16, 2017

Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections

A Phase 3 interventional study of Ingavirin (Imidazolyl Ethanamide Pentandioic Acid) and Placebo oral capsule in Influenza, Human, Acute Respiratory Infection and Common Cold, sponsored by Valenta Pharm JSC. Completed at 2 sites in Russian Federation. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-06-16.

Sponsored by Valenta Pharm JSC · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Registered 6 years 8 months after the study started (first participant enrolled Oct 2010, registered Jun 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Influenza, Human by Valenta Pharm JSC — 4 open to participants now, 4 under way, none of them phase 3. Influenza, Human · Valenta Pharm JSC.

Enrollment
2nd of 15
400 · median 240
Started
2010
with 1 other
Phase 3
7 of 15
none open now
Registered
3rd of 15
by date

Among the 15 studies in Influenza, Human by Valenta Pharm JSC, this one is the 2nd largest by enrollment, is one of 2 that started in 2010, is one of 7 in phase 3, and was the 3rd registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

4 of the 15 studies in Influenza, Human by Valenta Pharm JSC are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Influenza, Human by Valenta Pharm JSC, or all of them as a file.
02

Study summary

The purpose of the study was to evaluate efficacy of prophylactic Ingavirin intake by people having contact with sick people infected with influenza and other acute respiratory viral infections

Read the detailed description

The study includes 7 days of treatment period and 30 days of follow-up, 37 days total.

The participant was receiving Ingavirin or placebo for 7 days. Then during 30 days the participant was under supervision.

Visits were performed at days 2-7 (every day) since inclusion and then every 5 days during follow-up period.

Wherever during the study the participant developed symptoms of flu or other acute respiratory viral infection, the participant was taken for medical care to observe his condition, symptoms dynamics, lab tests, including laboratory verification of viral origin of the disease. Medical care was established for 10±2 days since symptoms. Everyday for 3 days and additional visits for 5±1 and 10±2 days of the disease.

The patient had the required symptomatic treatment, additionally the patient could be institutionalised if necessary.

Wherever the participant developed symptoms during treatment period, the patient was taken investigational drug on schedule.

03

Conditions studied

  • Influenza, Human
  • Acute Respiratory Infection
  • Common Cold
  • Flu
  • Viral Infection

Keywords

  • Profilaxis
  • Ingavirin
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who do have continuous contact with ill person (staff members, dormitory, family members), laboratory confirmed viral origin, during influenza/other acute viral respiratory disease season
  • First exposure with the ill person who is present with symptoms of flu or acute respiratory viral infection (fever, intoxication, catarrhal symptoms) ≤ 48 hours
  • Signed Informed Contest to participate in the study
  • throughout the study

Exclusion criteria

Exclusion Criteria:

  • Interferone or interferone inducers intake, or substances with action on immune system intake less then 3 months before inclusion
  • Anti-virals intake, other then drug, throughout the study
  • Vaccination for Influenza less than 1 year before inclusion
  • Pregnant or lactating
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
400 participants (actual)

Study arms

  • Experimental
    Ingavirin

    Ingavirin (Imidazolyl Ethanamide Pentandioic Acid) capsules, 90 mg once daily for 7 days

    Drug: Ingavirin (Imidazolyl Ethanamide Pentandioic Acid)

  • Placebo comparator
    Placebo

    Placebo oral capsule, once daily for 7 days

    Drug: Placebo oral capsule

Interventions

06

What researchers measure

Primary outcomes

  1. Difference in incidence of flu / other acute respiratory viral infections between Ingavirin and placebo groups

    To evaluate incidence difference between Ingavirin and placebo groups. Incidence defined as ratio between number of people got sick in the group to all people in the group. 1) Efficiency Index (EI) was defined as incidence of flu in placebo group to incidence of flu in Ingavirin group. 2) Efficacy Ratio (ER) defined by formula: ER=(incidence in placebo group - incidence Ingavirin group)\*100% then divided by incidence in placebo group.

    Time frame: Through study completion, an average of 37 days

Secondary outcomes

  1. Comparative evaluation of prevalence and duration of flu and acute viral respiratory infection at participants who developed flu / avri

    Time frame: Through study completion, an average of 37 days

07

Study locations

2 sites
  • Research Institute of Influenza
    Saint Petersburg, 197376, Russian Federation
  • Saratov State Medical University named after V. I. Razumovsky
    Saratov, 410012, Russian Federation
08

References and documents

Publications

  • Shul'diakov AA, Liapina EP, Kuznetsov VI. [Current principles in the chemoprophylaxis of acute respiratory viral infections]. Ter Arkh. 2013;85(11):27-33. Russian. PubMed 24432596 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2010 to primary completion in Apr 2011, 6 months.

Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 6 months is below that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2017
First posted
Jun 16, 2017
StartActual
Oct 3, 2010
Primary completionActual
Apr 19, 2011
CompletionActual
Oct 10, 2011
Last update
Jun 16, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03189537
Lead sponsor
Valenta Pharm JSC
Responsible party
Sponsor
First posted
Jun 16, 2017
Start date
Oct 3, 2010
Primary completion
Apr 19, 2011
Completion
Oct 10, 2011
Last update
Jun 16, 2017

Study contacts

Ekaterina Zakharova, MD, PhD
study director · Valenta Pharm JSC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pentanedioic acid imidazolyl ethanamide

Start the discussion